Refining the Role of Autophagy in Hypertrophic Cardiomyopathy

Shuyi Wang and Jun Ren*

University of Wyoming College of Health Sciences, USA

Submission: December 30, 2017; Published: April 20, 2018

*Corresponding author: Jun Ren, University of Wyoming College of Health Sciences, Laramie, USA, Tel: 1-307-766-6131; Fax: 1-307-766-2954; Email: jren@uwyo.edu

Abstract

Hypertrophic cardiomyopathy is perhaps the most prevalent form of inherited cardiomyopathy as a result of mutations in genes encoding components of the cardiac sarcomere. Although diagnosis of hypertrophic cardiomyopathy is relatively straightforward, its clinical management has been challenging due to lack of knowledge with regards to the precise pathogenesis of hypertrophic cardiomyopathy. A large body of evidence has recently suggested a pivotal role for impaired protein quality control machinery in inherited cardiomyopathies including hypertrophic cardiomyopathy. Here we will review recent findings on the role of autophagy in the etiology of hypertrophic cardiomyopathy and discuss therapeutic options available to restore autophagy-lysosomal function in an effort to benefit cardiac homeostasis in hypertrophic cardiomyopathy.

Keywords: Autophagy; Hypertrophic cardiomyopathy; Cardiac function.
role of autophagy in different forms of cardiomyopathies is distinct. Here we will briefly summarize limited data available on the role of autophagy in hypertrophic cardiomyopathy.

Changes in autophagy have been noted in hypertrophic cardiomyopathy (HCM) caused by Danon disease, Vici syndrome, and LEOPARD syndrome. In particular, autophagy flux was found to be suppressed in Danon disease, a genetic disorder with marked hypertrophic cardiomyopathy, likely as a result of deficiency in lysosome-associated membrane protein 2 (LAMP-2)[8]. LAMP-2 locates on lysosomal membrane and governs the fusion of autophagosome with lysosome. With LAMP-2 insufficiency in Danon disease, autophagosomes are unable to fuse with the lysosomes to initiate the lysosomal degradation process, resulting in large amount of vacuoles accumulated [9]. In Vici syndrome with prominent global developmental delay, skin hypopigmentation, nascent cataracts, microcephaly and hypertrophic cardiomyopathy, recessive mutation is evident in EPG5 (c.5870-1G>A) encoding a key autophagy regulator for autophagosome-lysosome fusion [10]. The condition presents usually early in life. In a recent study, autophagy was evaluated in hypertrophic cardiomyopathy patients carrying mutation of MYBPC3, encodes cardiac myosin-binding protein C (Mybpc3) and in a Mybpc3-targeted knock in hypertrophic cardiomyopathy mouse model. LC3-II protein levels were found elevated in septal myectomies from hypertrophic cardiomyopathy patients compared with non failing controls and in 60-week-old knock in mice compared with wild-type mouse hearts. Interestingly, autophagic flux was found to be blocked along with accumulation of residual bodies and glycogen. These authors identified that elevated Akt-mTORC1 (mammalian target of rapamycin complex 1) signaling was likely responsible for the blunt autophagy flux in mice with Mybpc3-targeted knockin hypertrophic cardiomyopathy, the effect of which was partially rescued by autophagy induction using rapamycin or caloric restriction[11]. Along the same line of Akt-MTOR overaction, recent findings from our group noted overt hypertrophic cardiomyopathy in mice with phosphatase and tens in homolog deleted from chromosome 10 (PTEN) knock out. Cardiomyocyte-specific PTEN knockout displayed the phenotype of established hypertrophic cardiomyopathy (HCM) as evidenced by unfavorable geometric, functional, and histological changes. Our data also revealed higher cardiac mTOR and suppressed cardiac autophagy. Treatment with autophagy inducer rapamycin reversed autophagy and hypertrophic cardiomyopathy in PTEN knockout mice [12]. These findings from patients carrying MYBPC3 mutations, and mice with Mybpc3-targeted knock in or PTEN deletion clearly suggested a role for defective autophagy (or autophagy flux) in the onset and development of hypertrophic cardiomyopathy, possibly through a mTOR hyperactivation-dependent mechanism.

Although data from our lab and others indicated the utility of autophagy induction in the therapy of experimental hypertrophic cardiomyopathy [11,12], there is still no drug therapy available for hypertrophic cardiomyopathy with heart transplantation being the only possible option. Danon disease is an X chromosome linked defect, and not surprisingly, LAMP2 may serve as the major drug target. Application of DNA methylation inhibitor to reactivate the randomly silenced LAMP2 gene has shown beneficial result in Danon disease, although such effect is limited to a subtype of female patients carrying a wide type allele which is randomly silenced [13]. No information is available with regards to the role of autophagy in DNA methylation inhibition-offered benefit here.

Drug development targeting autophagy remains challenging due to a number of practical issues. First, a series of steps are involved in autophagy and distinct defects may exist in different clinical situations (such as defect in early phase of autophagosome formation versus late autophagolysosome fusion), a drug that targets autophagy may produce drastically different effect in the treatment of cardiomyopathy, even though the main goal is the same in restoration of autophagy back to normal levels. Several pharmacological agents including bafilomycin, 3-MA, AICAR, and rapamycin are currently used for autophagy regulation, yet understanding of the complex steps and proteins involved still remains limited. Second, autophagy regulators may have off-target effect. An ideal agent should modulate target proteins and signaling pathways without eliciting any effects on other proteins. This may contribute to an unexpected side effect such as application of autophagy regulators in cancer therapy. At this time, limited agents are available with high specificity. Third, organ specificity may be an issue for pharmacotherapy targeting autophagy. Systemic delivery such as oral administration and IV infusion results in global distribution of the agent, which may or may not affect levels of autophagy elsewhere, especially in healthy organs or tissues. Liver toxicity, kidney toxicity may develop for therapeutic doses in the heart. It is quite challenging for targeted local delivery as the invasive nature may generate issues such as trauma, hemorrhage and inflammation.

Despite the challenges and obstacles in the drug development targeting autophagy, correction of autophagy derangement remains a promising avenue in the management of hypertrophic cardiomyopathy. Several aspects can be considered to overcome the aforementioned obstacles in autophagy drug therapy, including how the agent can generate its effect on cardiomyocytes. A number of approaches may be considered in the development of small molecule autophagy regulatory agents. In order to exhibit its local effect, an agent should be hydrophobic to allow diffusion across cell membrane into the intracellular space. Another option is to seek an agent with a natural receptor on the cell membrane where signal transduction can be achieved using the receptor-driven cell signaling regulation. Yet tissue/organ specificity remains a practical issue for the hunt for selective cardiac drugs for the regulation of autophagy in the management of hypertrophic cardiomyopathy.
How to cite this article:

References

Your next submission with Juniper Publishers will reach you the below assets
• Quality Editorial service
• Swift Peer Review
• Reprints availability
• E-prints Service
• Manuscript Podcast for convenient understanding
• Global attainment for your research
• Manuscript accessibility in different formats (Pdf, E-pub, Full Text, Audio)
• Unceasing customer service

Track the below URL for one-step submission
https://juniperpublishers.com/online-submission.php